2 enrolling by invitation. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Enrolling by invitation 2 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Shingrix, vaccination with 2 doses of Shingrix vaccine - Systemic Vasculitis, Spondylarthropathies | Phase 4 | Enrolling by invitation | Region Skane | 240 | 2024-12-17 | 2025-01-10 |
Arthritis (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Asthma (1) · Churg-Strauss Syndrome (1) · Giant Cell Arteritis (1) · Herpes Zoster (1) · Polymyalgia Rheumatica (1) · Pulmonary Eosinophilia (1) · Scleroderma, Diffuse (1) · Spondylarthropathies (1)
Autoimmune Diseases (2) · Cardiovascular Diseases (2) · Immune System Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Vascular Diseases (2) · Vasculitis (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arteritis (1) · Autoimmune Diseases of the Nervous System (1) · Bone Diseases (1) · Brain Diseases (1) · Bronchial Diseases (1) · Central Nervous System Diseases (1)
Injections (1) · Vaccination (1) · mepolizumab (1)
Azienda Ospedaliero Universitaria di Cagliari (1) · Region Skane (1)
Italy (1) · Sweden (1)
2023 (1)